| 2026-05-04 |
详情>>
内部人交易：
LOSCALZO JOSEPH共交易8笔
|
| 2026-04-29 |
详情>>
股本变动：
变动后总股本16526.26万股
|
| 2026-04-29 |
详情>>
业绩披露：
2026年一季报每股收益-0.56美元,归母净利润-9252.8万美元,同比去年增长37.03%
|
| 2026-04-29 |
财报披露：
美东时间 2026-04-29 盘前发布财报
|
| 2026-04-23 |
股东大会：
将于2026-06-04召开股东大会
会议内容 ▼▲
- 1.To elect our nominees, Spencer R. Berthelsen and Joan E. Herman, to our Board of Directors to serve as directors for a three-year term;
2.To make an advisory vote on executive compensation;
3.To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares;
4.To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan;
5.To ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2026 fiscal year;
6.To transact any other business that may be properly presented at the Annual Meeting.
|
| 2026-02-26 |
详情>>
业绩披露：
2023年年报每股收益-2.56美元,归母净利润-3.66亿美元,同比去年增长-35.8%
|
| 2026-02-26 |
详情>>
业绩披露：
2025年年报每股收益-2.38美元,归母净利润-3.81亿美元,同比去年增长15.97%
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.95美元,归母净利润-1.52亿美元,同比去年增长56.52%
|
| 2025-09-22 |
复牌提示：
2025-09-22 06:55:00 停牌，复牌日期 2025-09-22 07:30:00
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-0.15美元,归母净利润-2338.7万美元,同比去年增长88.81%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.93美元,归母净利润-1.47亿美元,同比去年增长-2.9%
|
| 2025-04-25 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.To elect our nominees, Allene M. Diaz, Michael Hayden, Joseph Klein, III, and Joseph Loscalzo, to our Board of Directors to serve as directors for a three-year term;
2.To make an advisory vote on executive compensation;
3.To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares;
4.To ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2025 fiscal year;
5.To transact any other business that may be properly presented at the Annual Meeting.
|
| 2025-02-19 |
详情>>
业绩披露：
2022年年报每股收益-1.9美元,归母净利润-2.7亿美元,同比去年增长-843.18%
|
| 2025-02-19 |
详情>>
业绩披露：
2024年年报每股收益-3.04美元,归母净利润-4.54亿美元,同比去年增长-23.92%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.38美元,归母净利润-3.5亿美元,同比去年增长2.09%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-1.43美元,归母净利润-2.09亿美元,同比去年增长0.26%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.98美元,归母净利润-1.43亿美元,同比去年增长-14.86%
|
| 2024-04-25 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect our nominees, Brett P. Monia and Michael Yang, to our Board of Directors to serve as Directors for a three-year term.
2.To make an advisory vote on executive compensation.
3.To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards.
4.To ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2024 fiscal year.
5.To transact any other business that may be properly presented at the Annual Meeting.
|
| 2023-04-20 |
股东大会：
将于2023-06-01召开股东大会
会议内容 ▼▲
- 1.To elect our nominees, Spencer R. Berthelsen, Joan E. Herman, B. Lynne Parshall, and Joseph H. Wender, to our Board of Directors to serve as Directors for a three-year term;
2.To make an advisory vote on executive compensation;
3.To make an advisory vote on the frequency of future advisory votes on executive compensation;
4.To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares;
5.To ratify increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years;
6.To ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2023 fiscal year;
7.To transact any other business that may be properly presented at the Annual Meeting.
|
| 2022-04-20 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.To elect our nominees, Allene M. Diaz, Michael Hayden, Joseph Klein, III, and Joseph Loscalzo, to our Board of Directors to serve as Directors for a three-year term;
2.To make an advisory vote on executive compensation;
3.To ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2022 fiscal year.
4.To transact any other business that may be properly presented at the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.elect our nominees, Brett Monia, Frederick Muto, and Peter Reikes, to our Board of Directors to serve as Directors for a three-year term;
2.approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 6,700,000 shares to an aggregate of 29,700,000 shares and add a fungible share counting ratio;
3.make an advisory vote on executive compensation;
4.ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2021 fiscal year.
5.Transact any other business that may be properly presented at the Annual Meeting.
|
| 2020-04-24 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1.elect Joseph Wender, B. Lynne Parshall, Spencer Berthelsen and Joan Herman to serve as Directors for a three-year term;
2.approve an amendment and restatement of the Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors’ Stock Option Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under such plan by 800,000 shares to an aggregate of 2,800,000 shares, reduce the amount of the automatic awards under the plan, revise the vesting schedule of awards and extend the term of the plan;
3.ratify amending the existing stock option and restricted stock unit awards of directors to adjust vesting;
4.make an advisory vote on executive compensation;
5.ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2020 fiscal year.
|
| 2019-04-26 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.elect Stanley T. Crooke, Joseph Klein, III, Joseph Loscalzo and Michael Hayden to serve as Directors for a three-year term;
2.make an advisory vote, ratifying the appointment of Peter N. Reikes to fill a vacancy on our Board of Directors for a two-year term;
3.make an advisory vote, ratifying the appointment of Brett Monia to fill a vacancy on our Board of Directors for a two-year term;
4.approve an amendment and restatement of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2011 Equity Incentive Plan by 7,000,000 to an aggregate of 23,000,000 shares;
5.make an advisory vote on executive compensation;
6.ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2019 fiscal year.
|
| 2018-04-11 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.elect Frederick T. Muto and Breaux B. Castleman to serve as Directors for a three-year term;
2.make an advisory vote on executive compensation;
3.ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2018 fiscal year.
|
| 2017-04-10 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1.elect Spencer R. Berthelsen, B. Lynne Parshall and Joseph H. Wender to serve as Directors for a three-year term;
2.approve an amendment to the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2011 Equity Incentive Plan by 5,000,000 to an aggregate of 16,000,000 shares;
3.make an advisory vote on executive compensation;
4.make an advisory vote on the frequency of future advisory votes on executive compensation;
5.ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for our 2017 fiscal year.
·
Transact any other business that may be properly presented at the Annual Meeting.
|